Holen Sie sich die Stockscreener-App
0.4547
5.21%
0.0225
Handel nachbörslich:
.45
-0.0047
-1.03%
Schlusskurs vom Vortag:
$0.4322
Offen:
$0.44
24-Stunden-Volumen:
1.41M
Relative Volume:
0.54
Marktkapitalisierung:
$18.92M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-74.56M
KGV:
-0.2483
EPS:
-1.8316
Netto-Cashflow:
$-60.27M
1W Leistung:
+14.82%
1M Leistung:
+34.53%
6M Leistung:
-48.05%
1J Leistung:
-67.29%
1-Tages-Spanne:
$0.43
$0.495
1-Wochen-Bereich:
$0.36
$0.495
52-Wochen-Spanne:
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Vergleichen Sie RLYB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.4547 | 16.48M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-10 | Eingeleitet | Wedbush | Outperform |
| 2022-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-08-23 | Eingeleitet | Cowen | Outperform |
| 2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - TradingView
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Access to Investment Community - Newser
What makes Rallybio Corporation stock price move sharplyFree Stock Selection with 300% Return - Newser
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - TradingView
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha
Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com
Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - Business Wire
ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan
Rallybio Finalizes Employment Agreement with CMO - TipRanks
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization - TipRanks
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk - TipRanks
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 By Investing.com - Investing.com South Africa
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - BioSpace
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 - Investing.com India
Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study - MarketScreener
Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders - Stock Titan
RLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - mx.advfn.com
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Reports Q1 2025 Financial Results and Strategic Updates - MSN
New Haven biotech firm to cut 40% of workforce in latest round of layoffs, pivots on drug program - Stamford Advocate
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):